(Q34722162)

4 August 2017

1 reference

title

Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation (English)

1 reference

4 August 2017

0 references

organ transplantation

1 reference

1

Green M

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

American Journal of Transplantation

4 August 2017

published in

1 reference

4 August 2017

volume

1

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

103-108

1 reference

The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

Pretransplantation assessment of the risk of lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10202.X

7 January 2021

10.1034/J.1600-6143.2001.10202.X

Identifiers

DOI

1 reference

4 August 2017

1 reference